top of page
Zum_Research_graph_smaller.png
zumXr_logo_color.png
zumxr-extended-release-caffeine-1.webp
zumxr-delayed-release-caffeine-1.webp

Modified Release Profiles 

zümXR® delivers caffeine in a timed release and extended manner, as compared to standard (immediate release) caffeine. The release profile of zümXR® is also more favorable when compared to competitors in the indutry.

Utility

This release profile allows for the traditional enhancements of caffeine, but also mitigates the common pitfalls of caffeine. 

Caffeine with modified release times has utility in sports nutrition and exercise performance. Athletes who desire a extended circulating levels of caffeine can benefit from the release profiles. Non-exercising populations also see use in the cognitive, mood, and energy level applications of the technology. 

Extended Release

zümXR® Extended Release Caffeine provides all day energy and lasting endurance. Not only does it have utility in the workout and nutrition space, but as well as workplace environments, extensive study sessions, and for combining with other daily energy products. 

The release profile for zümXR® Extended Release Caffeine is <55% within 1 Hour and >80% within 6 hours. 

Delayed Release 

zümXR® Delayed Release Caffeine provides energy for pre-workouts and intra-workouts, as well as endurance activities, and in combination with other daily energy products. The release profile is seemingly favorable amongst consumers who are looking for a boost at hour 1 and 2 into their activity. 

The release profile for zümXR® Delayed Release Caffeine is <25% within 1 hour and >80% within 2 hours. 

Image by Wesley Tingey

First Ever PK Study 

The first ever clinical study on extended release caffeine was a pharmacokinetic (PK) study with human participants designed to test the efficacy of zümXR®.

The results of this study depict a dramatic increase in caffeine half-life of zümXR® Extended Release Caffeine compared to immediate release caffeine. 

 

In a randomized, double-blind, two-way crossover pharmacokinetic (PK) study, with immediate release caffeine (anhydrous) and zümXR® Extended Release Caffeine, PK parameters were evaluated. 

The primary objective was to compare plasma levels of caffeine between groups after providing participants with equal amounts of caffeine (250mg).

The secondary objectives were to characterize the relative absorption and PK characteristics and the assess the safety profile (vital signs - blood pressure, heart rate ) of the immediate release caffeine (IRC) and Extended Release Caffeine (ERC).

bottom of page